Healthcare

•U.S. surgical cases using Saluda's technology have commenced, marking the start of commercial rollout.

•Ryoncil and the chronic lower-back-pain program remain the central commercial opportunities.

Shares in EBR Systems (ASX:EBR) gained during theTrading sessionon 7 September 2026. The move came on a mixed session for the wider market, with the S&P/ASX 200 broadly flat even as information technology stocks fell sharply, underscoring how selectively investors were treating growth and …

Cynata Therapeutics entered a major clinical-data period in 2026, with Phase 3 osteoarthritis and Phase 2 acute graft-versus-host disease trials providing key catalysts. The company completed aCapitalraising in May to strengthen its cash position ahead of the readouts. Cynata’s proprietary Cymerus stem-cell platform remains …

Chimeric Therapeutics has recently faced a significant setback in its CHM-2101 CDH17 CAR-T program after dose-limiting toxicities at Dose Level 3 led to cessation of enrolment and dosing in the Phase 1 trial. The company is reassessing the development strategy while continuing its broader …

Ceryvyn Therapeutics completed its transition from Opthea during July 2026, adopting the CYV ticker and repositioning itself as a biotechnology company focused on rare-disease therapeutics. Its FY2026 reporting confirms the new corporate identity and ongoing development strategy. The company remains focused on advancing its …

Unlike many small-cap medical-technology hopefuls, Aroa is not a pre-revenue story. The company recorded positiveEarnings Per Shareof around 1.1 cents and carries aBook Valuenear 23.6 cents per share, with noDividendasCapitalis retained to fund expansion. That distinction matters: it shifts the debate from survival to …